Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 13;69(1):7.
doi: 10.1007/s00005-021-00603-y.

Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus

Affiliations
Review

Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus

Wen-Yan Tang et al. Arch Immunol Ther Exp (Warsz). .

Abstract

Systemic lupus erythematosus (SLE) is a rare, heterogeneous autoimmune and autoinflammatory disease that affects both sexes and all races, although this disease exhibits its highest incidence/prevalence among the black population and shows a predilection for women of reproductive age. Although SLE has no cure, treatment can help decrease its signs and symptoms. Thus, we should focus primarily on personalized treatment. Mesenchymal stem/stromal cells (MSCs), which are multipotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes, and myoblasts, among other cell types, are potential candidates for use in a promising strategy to treat severe and refractory SLE. MSCs have an immunomodulatory function that can suppress the proliferation and activities of many immune cells, such as T lymphocytes, B lymphocytes, natural killer cells, macrophages and dendritic cells. Substantial progress has recently been made in MSC therapy, and experimental and clinical data suggest that such a therapy is a promising strategy for the treatment of severe and refractory SLE. In this review, we highlight the effects of MSCs on different immune cell types, describe the mechanisms underlying MSC-mediated immunoregulation, and discuss the treatment of SLE with MSCs from different sources in various animal models and clinical applications.

Keywords: Application; Mesenchymal stem cells; Systemic lupus erythematosus; Transplantation.

PubMed Disclaimer

References

    1. Akiyama K, Chen C, Wang D et al (2012) Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10:544–555 - PubMed - PMC
    1. Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32:252–260 - PubMed - PMC
    1. Arnaud L, Nordin A, Lundholm H et al (2017) Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with systemic lupus erythematosus or systemic sclerosis. Arthritis Rheum 69:1272–1279
    1. Asari S, Itakura S, Ferreri K et al (2009) Mesenchymal stem cells suppress B-cell terminal differentiation. ExpHematol 37:604–615
    1. Bai L, Lennon DP, Caplan AI et al (2012) Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 15:862–870 - PubMed - PMC

MeSH terms

LinkOut - more resources